In recent years, there has been virtually no IPO activity in the medical device arena; the only viable exit option for private investors was trade sale. Yet while M&A activity remains strong, 2004 has witnessed a rekindling of public investor interest in the sector.
Perhaps encouraged by successes in the biotech space, where companies like Eyetech Pharmaceuticals Inc. and Pharmion Corp. among...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?